Profectus pockets $9.5M for Ebola vaccine; AbbVie shying away from big deals;

@FierceBiotech: $IPXL cans 25% of its R&D staff in a cost-cutting gambit. More | Follow @FierceBiotech

@JohnCFierce: FDA to $SRPT's CEO: You don't hear so well. And that's something you don't see much. Great piece by @DamianFierce. Article | Follow @JohnCFierce

@DamianFierce: Six of @ClevelandClinic's Top 10 Medical Innovations are drugs, and here's a bunch of words on them. Story | Follow @DamianFierce

@EmilyMFierce: What about effect of radiation on adults? Aggressive thyroid cancers in children linked to radiation exposure. News | Follow @EmilyMFierce

> Profectus BioSciences has locked down $9.5 million in Department of Defense funding to help it develop a trivalent vaccine for Ebola and Marburg. The cash will support manufacturing and prelinical testing for the vaccine, the company said. More

> With its $55 billion deal for Shire ($SHPG) firmly in the rear-view mirror, AbbVie ($ABBV) isn't scouting for another megamerger any time soon, CEO Richard Gonzalez said. Story

> U.S. Rep. Michael McCaul plans to propose a bill that would require drugmakers to disclose their internal compassionate-use policies, according to The Wall Street Journal, hoping to shed light on how the industry decides whether to allow its in-development drugs to be administered pre-approval. News

Medical Device News

@FierceMedDev:  AliveCor heart monitor, app added to GreatCall's health-focused smartphone. More | Follow @FierceMedDev

@VarunSaxena2: Chinese government urges hospitals to buy local devices. Story | Follow @VarunSaxena2

@EmilyWFierce: Johnson & Johnson weighs $250M settlement to resolve more hip implant claims. Article | Follow @EmilyWFierce

@MichaelGFierce: @HarvardResearch team uses stem cells to deliver toxic doses to #cancer cells. More | Follow @MichaelGFierce

> Medtronic discloses new corporate structure upon Covidien deal close. More

> Zimmer Biomet will be created amid executive shake-up. Story

Pharma News

@FiercePharma: Jobs saved as Boehringer Ingelheim finds Chinese buyer for U.S. plant set to close. Story | Follow @FiercePharma

@EricPFierce: ICYMI: Novorossiya hiring 90 workers for its new plant in New Hampshire. More from FiercePharmaManufacturing | Follow @EricPFierce

@CarlyHFierce: Top-read in FierceVaccines Thursday: Pfizer beats out Novartis with FDA MenB nod. Article | Follow @CarlyHFierce

> After strong Q3, no $55B deals in AbbVie's future, CEO says. But a smaller one? Maybe. More

> Cipla petitions India to revoke Novartis respiratory drug patents, launches low-cost version of drug. News

Suggested Articles

Californian RNA biotech Arrowhead will lose its COO and R&D head from next year but is hiring a new CMO and CSO to help steady its research exec team.

The biotech began testing the small molecule in a phase 3 trial of heavily pretreated small cell lung cancer patients late last year. 

Roche is spending up to $1.4 billion to snap up a scarring-focused biotech, nabbing an FDA breakthrough-tagged therapy in the process.